CD274 and hepatocellular carcinoma: Ipilimumab, an anti‐CTLA‐4 inhibitor, has emerged as a promising therapeutic option when combined with anti‐PD‐1/PD‐L1 agents in advanced HCC, as evidenced by recent phase III trials such as CheckMate 9DW and HIMALAYA [16].